logo
#

Latest news with #Pharmaceutical

Concord Biotech rises 2% on incorporating its arm for marketing and sales
Concord Biotech rises 2% on incorporating its arm for marketing and sales

Business Standard

time7 hours ago

  • Business
  • Business Standard

Concord Biotech rises 2% on incorporating its arm for marketing and sales

Concord Biotech shares rose 2.3 per cent, logging an intraday high at ₹1941.25 per share on the BSE. At 1:22 PM, Concord Biotech share price was trading 1.72 per cent higher at ₹1,930 per share on BSE. In comparison, the BSE Sensex rose 0.43 per cent to 82,544.23. The market capitalisation of the company stood at ₹20,190.93 crore. The 52-week high of the company stood at ₹2,658 per share, and the 52-week low was at ₹1,370.05. Why were Concord Biotech shares buzzing in trade? The buying on the counter came after the company incorporated its subsidiary Concord Lifegen, with an objective to carry out marketing, sales, and distribution of pharmaceutical products. The total cost of acquisition is worth ₹1,00,000. "We are pleased to announce incorporation of Concord's Wholly Owned subsidiary company, namely, 'Concord Lifegen Limited' with objective to carry out marketing, sales, and distribution of pharmaceutical products," the filing read. Its primary objectives include executing targeted sales strategies, ensuring regulatory compliance across domestic and international markets, handling logistics and customer support, and maintaining transparent reporting to the holding company, according to the filing. The authorised share capital (as on July 22, 2025) of Concord Lifegen is ₹1,00,000 divided into 10,000 equity shares of ₹10 each issued share capital (as on July 22, 2025). That apart, in Q4, the company's profit climbed 47.8 per cent year-on-year (Y-o-Y) to ₹140 crore in the March quarter of FY25, from ₹95 crore in the March quarter of FY24. Concord Biotech's revenue from operations surged 34.8 per cent Y-o-Y to ₹429.9 crore in Q4FY25, from ₹319 crore in the same quarter a year ago. About Concord Biotech Concord Biotech is a research-driven biopharmaceutical company specialising in the production of Active Pharmaceutical Ingredients (APIs) through fermentation and semi-synthetic processes, along with finished formulations. Initially a single-product entity, Concord has evolved into a comprehensive solutions provider, offering a broad range of products across various therapeutic segments. The company has established a global presence, distributing its products in over 70 countries, including key markets like the USA, Europe, Japan, and Latin America, while also maintaining a major footprint in India.

Better Growth Buy: Eli Lilly vs. Viking Therapeutics
Better Growth Buy: Eli Lilly vs. Viking Therapeutics

Globe and Mail

timea day ago

  • Business
  • Globe and Mail

Better Growth Buy: Eli Lilly vs. Viking Therapeutics

Key Points Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares. One of these drug stocks is the safer bet, but the other could have more upside potential. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) and Viking Therapeutics (NASDAQ: VKTX) have garnered considerable attention over the past year due to their solid clinical progress. However, these drugmakers have also lagged the market over the trailing-12-month period. That said, there are good reasons to expect both to bounce back and perform well over the long run. But which is a better stock to invest in today? Let's find out. The case for Eli Lilly Eli Lilly is a well-established pharmaceutical leader that consistently generates revenue and earnings. The company's top line has been growing much faster than those of its peers in recent quarters. In the first quarter, Lilly's revenue increased by 45% year over year to $12.7 billion, while net income of $2.8 billion came in 23% higher than the year-ago period. Lilly owes this performance to several medicines, especially Mounjaro for diabetes and Zepbound for weight management. Its lineup features other blockbusters, including cancer drug Verzenio and immunosuppressant Taltz. Newer therapies, like Alzheimer's disease medicine Kisunla and eczema treatment Ebglyss, could also eventually contribute meaningfully to its top line. And in the foreseeable future, the company is poised to be a leader in the rapidly growing anti-obesity market. It's developing several exciting medicines in this field, including orforglipron, an oral GLP-1 candidate. Orforglipron recently aced a phase 3 study in diabetes, and it's undergoing late-stage trials in obesity. Lilly's pipeline also features other promising investigational weight loss therapies such as retatrutide. Beyond its core area of therapeutic expertise, Lilly has a robust pipeline across oncology, immunology, and other fields. The company's innovative abilities should serve it well over the long run. Lastly, Eli Lilly is a top dividend stock: The company has increased its payouts by 200% in the past decade. Even after a terrific run over the past five years, the stock should still deliver above-average returns to patient investors. The case for Viking Therapeutics Viking Therapeutics rose to fame last year when its leading candidate, VK2735, aced a mid-stage trial in the fast-growing area of weight management; the drug was recently moved to phase 3 studies. The biotech is now developing an oral formulation of VK2735, which is currently undergoing a phase 2 trial. Viking should report results from this study by the end of the year, and positive results could jolt the stock. Another investigational medicine entering late-stage studies, VK2809, is a potential therapy for metabolic dysfunction-associated steatohepatitis (MASH) that could become an important product for the company. Last year, the U.S. Food and Drug Administration approved the first medicine specifically for MASH. There's a massive unmet need in this field, with an estimated 9 million people in the U.S. who live with clinically significant MASH-related liver disease, so there's room for many newer medicines; Viking's VK2809 may join the mix eventually. The company -- which targets conditions with vast or unmet needs -- is also developing VK0214 as a therapy for X-linked adrenoleukodystrophy (X-ALD), a debilitating rare genetic disorder of the nervous system. There is currently no medicine for X-ALD. Like most clinical-stage biotechs, Viking Therapeutics doesn't yet generate revenue and operates at a loss. However, consistent clinical and regulatory progress could send the company's shares soaring. The verdict Which one of these two stocks should you consider buying? If you had to choose, it might depend on your goals and risk tolerance. Eli Lilly is the safer bet, as it has a deep lineup and pipeline of products, generates significant revenue that has been growing at a steady clip, and is consistently profitable. Lilly also pays a dividend. It's the better choice for risk-averse, income-seeking investors. One potential issue with the pharmaceutical giant may be its valuation. Its recent forward price-to-earnings (P/E) ratio of 36.8 is more than twice the healthcare industry's average of 16. But the stock is arguably worth it, given its terrific growth prospects. What about Viking Therapeutics? The smaller drugmaker could have significantly more upside than its larger peer, but only if it can deliver strong clinical data for its two leading candidates. The flip side is that it's riskier. Its shares will plunge if it faces severe setbacks, especially with its leading program, VK2735. But it remains a decent choice for investors with a larger appetite for risk. If that describes you, you may want to initiate a small position in the stock and progressively add more as the company proves itself. Should you invest $1,000 in Eli Lilly right now? Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025

Glioma Pipeline Appears Promising With 180+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment
Glioma Pipeline Appears Promising With 180+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment

Globe and Mail

time2 days ago

  • Business
  • Globe and Mail

Glioma Pipeline Appears Promising With 180+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment

DelveInsight's, ' Glioma Pipeline Insight, 2025 ' report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Glioma pipeline landscape. It covers the Glioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glioma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Glioma Pipeline. Dive into DelveInsight's comprehensive report today! @ Glioma Pipeline Outlook Key Takeaways from the Glioma Pipeline Report In July 2025, Eli Lilly and Company announced a study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy. In July 2025, Istari Oncology Inc. announced a Phase 2 study of lerapolturev, an oncolytic polio/rhinovirus recombinant, in adult patients with recurrent World Health Organization (WHO) grade IV malignant glioma. The objective of this study is to investigate the safety and efficacy (anti-tumor response and survival) of lerapolturev in recurrent WHO grade IV malignant glioma. In July 2025, Incyte Corporation conducted a study of pemigatinib in participants with recurrent glioblastoma (GBM) or other recurrent gliomas, circumscribed astrocytic gliomas, and glioneuronal and neuronal tumors with an activating FGFR1-3 mutation or fusion/rearrangement. This study consists of 2 cohorts, Cohorts A, and B, and will enroll approximately 82 participants into each cohort. Participants will receive pemigatinib 13.5 mg QD on a 2-week on-therapy and 1-week off-therapy schedule as long as they are receiving benefit and have not met any criteria for study withdrawal. In July 2025, Nuvation Bio Inc. organized a 2-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma. DelveInsight's Glioma pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Glioma treatment. The leading Glioma Companies such as CellabMED, Oblato, BioMed Valley Discoveries, PharmAbcine, I-Mab Biopharma, Chimerix, Medicenna Therapeutics, Daiichi Sankyo, Eli Lilly and Company, Candel Therapeutics, AstraZeneca, Aveta Biomics, Angiochem, Arog Pharmaceuticals, Boehringer Ingelheim, BioMimetix, Bexion Pharmaceuticals, CANbridge Life Sciences, Crimson Biopharma, Epitopoietic Research Corporation, Stemgen and others. Promising Glioma Pipeline Therapies such as DS-1001b, Nimotuzumab, Radiotherapy, AP23573, BLZ-100, LY2157299, Temozolomide, Safusidenib, ONC201, PLB1001, YYB-103, and others. Stay ahead with the most recent pipeline outlook for Glioma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Glioma Treatment Drugs Glioma Emerging Drugs Profile AV-GBM-1: Aivita Biomedical, Inc. AV-GBM-1 is an innovative immunotherapy developed by AIVITA Biomedical, Inc., specifically targeting glioblastoma (GBM), one of the most aggressive forms of brain cancer. This treatment utilizes autologous dendritic cells that are loaded with autologous tumor neoantigens derived from tumor-initiating cells. The therapy is administered through a series of subcutaneous injections and aims to enhance the immune response against the patient's unique cancer profile. Currently, the drug is in phase III stage of its clinical trial for the treatment of Glioma. DB 107: Denovo BioPharma Denovo BioPharma's DB107 is an investigational gene therapy designed to treat high-grade gliomas, including glioblastoma (GBM), a particularly aggressive form of brain cancer. The therapy utilizes a novel biomarker-guided approach, leveraging the Denovo Genomic Marker 7 (DGM7) to identify patients who are likely to benefit from the treatment. Currently, the drug is in phase II stage of its clinical trial for the treatment of Glioma. MDNA55: Medicenna Therapeutics, Inc. MDNA55 is a therapeutic for recurrent glioblastoma multiforme (rGBM), a uniformly fatal form of brain cancer. By using a highly specific IL-4 Superkine as the vehicle to deliver a potent bacterial toxin to the tumor cells, MDNA55 has the potential to purge bulk tumors and disrupt their supporting networks, while reactivating the immune system to tackle cancer. MDNA55 is designed to be a molecular trojan horse. It is a genetic fusion of two molecules: a circularly permuted IL-4 Superkine and the catalytic domain of the pseudomonas exotoxin A. Genetic fusion allows MDNA55 to harness the selectivity of the Superkine for cancers that overexpress the target IL-4 receptor (IL-4R) and deliver the cell-killing toxin directly into the tumor, its microenvironment and cancer stem cells. Since the IL-4 receptor is not found in a healthy brain and the exotoxin is only active in the cancer cell cytoplasm, this helps ensure that healthy cells are unaffected. When MDNA55 binds the target IL-4R, it is swallowed inside the tumor cell through a process called endocytosis. Once inside the tumor, proteases cleave the drug and activate the catalytic domain of the exotoxin to begin the process of apoptosis (cell death) involving a protein called elongation factor-2. Currently, the drug is in phase II stage of its clinical trial for the treatment of Glioma. Abemaciclib: Eli Lilly and Company Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with Fulvestrant. Following oral treatment in patients with HR-positive, HER2-negative breast cancer, abemaciclib demonstrated increased progression-free survival rates and objective response rates. Abemaciclib has been used in trials studying the treatment of melanoma, lymphoma, neoplasm, solid tumor, and glioblastoma. NMS-03305293: Nerviano Medical Sciences NMS-293 is a second generation PARP inhibitor that differentiates from other approved or advanced molecules in its unique selectivity for PARP1 vs. PARP2 enzymes and low DNA trapping activity, both features potentially linked to lower hematological toxicity and higher potential for combination with DNA damaging agents in a wide range of tumors, covering high unmet medical needs. It also has a superior ability to penetrate the blood-brain barrier, a very important feature supporting its utilization in CNS tumors and brain metastases. The drug has shown high anti-tumor activity as single agent in BRCA mutated preclinical tumor models and synergy and tolerability in combination with chemotherapy. Based on the findings, NMS-293 is currently in clinical developmental Phase II in combination with temozolomide in recurrent glioblastoma. CAN-3110: Candel Therapeutics CAN-3110 is a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate designed with dual activity for oncolysis and immune activation in a single therapeutic. Its activity is designed to be conditional to the expression of Nestin in cancer cells. CAN-3110 is being evaluated in a phase I investigator-sponsored clinical trial in patients with recurrent HGG. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Glioma. MB-101: Mustang Bio MB-101 is an IL13Rα2-targeted CAR T cell therapy developed by Mustang Bio, aimed at treating recurrent glioblastoma (GBM) and high-grade gliomas. Currently, the drug is in Phase I stage of clinical trial for the treatment of Glioma. The Glioma Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Glioma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glioma Treatment. Glioma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Glioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Glioma market Explore groundbreaking therapies and clinical trials in the Glioma Pipeline. Access DelveInsight's detailed report now! @ New Glioma Drugs Glioma Companies CellabMED, Oblato, BioMed Valley Discoveries, PharmAbcine, I-Mab Biopharma, Chimerix, Medicenna Therapeutics, Daiichi Sankyo, Eli Lilly and Company, Candel Therapeutics, AstraZeneca, Aveta Biomics, Angiochem, Arog Pharmaceuticals, Boehringer Ingelheim, BioMimetix, Bexion Pharmaceuticals, CANbridge Life Sciences, Crimson Biopharma, Epitopoietic Research Corporation, Stemgen and others. Glioma Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intra-articular Intraocular Intrathecal Intravenous Oral Parenteral Subcutaneous Topical Transdermal Glioma Products have been categorized under various Molecule types, such as Oligonucleotide Peptide Small molecule Unveil the future of Glioma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Glioma Market Drivers and Barriers Scope of the Glioma Pipeline Report Coverage- Global Glioma Companies- CellabMED, Oblato, BioMed Valley Discoveries, PharmAbcine, I-Mab Biopharma, Chimerix, Medicenna Therapeutics, Daiichi Sankyo, Eli Lilly and Company, Candel Therapeutics, AstraZeneca, Aveta Biomics, Angiochem, Arog Pharmaceuticals, Boehringer Ingelheim, BioMimetix, Bexion Pharmaceuticals, CANbridge Life Sciences, Crimson Biopharma, Epitopoietic Research Corporation, Stemgen and others. Glioma Pipeline Therapies- DS-1001b, Nimotuzumab, Radiotherapy, AP23573, BLZ-100, LY2157299, Temozolomide, Safusidenib, ONC201, PLB1001, YYB-103, and others. Glioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Glioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Glioma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Glioma Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Glioma Disease: Overview Pipeline Therapeutics Therapeutic Assessment Glioma Disease– DelveInsight's Analytical Perspective Late Stage Products (Phase III) AV-GBM-1: Aivita Biomedical, Inc. Drug profiles in the detailed report….. Mid Stage Products (Phase II) DB 107: Denovo BioPharma Drug profiles in the detailed report….. Early Stage Products (Phase I) MB-101: Mustang Bio Preclinical Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products Glioma Disease Key Companies Glioma Disease Key Products Glioma Disease- Unmet Needs Glioma Disease- Market Drivers and Barriers Glioma Disease- Future Perspectives and Conclusion Glioma Disease Analyst Views Glioma Disease Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:

Breast Cancer Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment
Breast Cancer Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment

Globe and Mail

time7 days ago

  • Business
  • Globe and Mail

Breast Cancer Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment

DelveInsight's, ' Breast Cancer Pipeline Insight 2025 ' report provides comprehensive insights about 100+ Breast Cancer companies and 120+ pipeline drugs in the Breast Cancer pipeline landscape. It covers the Breast Cancer pipeline drugs profiles, including clinical and nonclinical stage products. It also covers the Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Breast Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Breast Cancer Pipeline Outlook Key Takeaways from the Breast Cancer Pipeline Report In July 2025, Merck Sharp & Dohme LLC announced a study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer. In July 2025, Pfizer announced a clinical study is to learn about the safety and effects of the study medicine (called disitamab vedotin) for the possible treatment of people with breast cancer that is hard to treat and has spread in the body (advanced cancer). In July 2025, AstraZeneca conducted a study is to look at the effectiveness, safety, and antitumor activity of study drugs MEDI4736 in combination with olaparib (modules 1, 2, 3, 4, 5 and 7) and MEDI4736 in combination with olaparib and bevacizumab (module 6). It will also examine what happens to the study drugs in the body and investigate how well the combination between MEDI4736, olaparib and bevacizumab is tolerated. DelveInsight's Breast Cancer pipeline report depicts a robust space with 100+ Breast Cancer companies working to develop 120+ pipeline therapies for Breast Cancer treatment. The leading Breast Cancer Companies such as Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc., Horizon Therapeutics, and others. Promising Breast Cancer Pipeline Therapies such as Oraxol, ARV-471, Ribociclib, E7389, Trastuzumab, GM-CSF, GM-CSF, Trastuzumab, Paclitaxel, Gemcitabine/Carboplatin, Iniparib, and others. Stay ahead with the most recent pipeline outlook for Breast Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Breast Cancer Treatment Breast Cancer Emerging Drugs Profile SHR-A1811: Jiangsu HengRui Medicine Co., Ltd. SHR-A1811 is an innovative HER2-targeted antibody-drug conjugate with a topoisomerase I payload conjugated to an anti-HER-2 mAb by a cleavable linker. Once bound to HER2 expressing tumor cells, the ADC is internalized and the linker releases the toxin, leading to tumor cell death. It can bind to the cell membrane surface of HER2 expressing cells, and then enter the cells to reach the lysosome to release small Molecular toxins eventually induce tumor cell apoptosis, combining the high targeting of antibodies and the powerful killing power of cytotoxic drugs on target cells. Preclinical research results show that SHR-A1811 has good anti-tumor activity, safety, tolerability and pharmacokinetic characteristics, or can further improve drug resistance, enhance efficacy, meet clinical needs, and provide more cancer patients multiple choice. Currently, the drug is in the Phase III stage of its development for the treatment of Breast Cancer. HLX11: Shanghai Henlius Biotech HLX11 is a pertuzumab biosimilar developed by Henlius independently in line with relevant regulations and guidelines on biosimilars in China and the European Union (EU), which can be potentially used in combination with trastuzumab and chemotherapy as neoadjuvant or adjuvant treatment for HER2-positive early breast cancer and in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic or unresectable locally recurrent breast cancer patients. HLX11 can specifically bind with the subdomain II of HER2 extracellular domain and inhibit the heterodimerisation of HER2 and other HER family receptors, i.e., EGFR, HER3, and HER4. This will inhibit signal transduction of relevant pathways and lead to the stop of growth and apoptosis of tumour cells. In the meantime, HLX11 can also enhance the tumour-killing activity of immune cells via antibody-dependent cell cytotoxicity. Currently, the drug is in the Phase III stage of its development for the treatment of HER2 positive Breast Cancer. Praluzatamab ravtansine: CytomX Therapeutics Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and circulation. The tumor microenvironment is enriched for proteases capable of cleaving the linker, thereby releasing the mask, allowing for localized binding of CX-2009 to CD166. Currently, the drug is in the Phase II stage of its development for the treatment of Breast Cancer. MCLA-128 is an antibody-dependent cell-mediated cytotoxicity (ADCC) -enhanced Biclonics® that utilizes Merus Dock & Block® mechanism and inhibits the neuregulin/HER3 tumor-signaling pathway in solid tumors. MCLA-128 is believed to target the HER3 signaling pathway and to overcome the resistance of tumor cells to HER2-targeted therapies using two mechanisms: blocking growth and survival pathways to stop tumor expansion and recruitment and enhancement of immune effector cells to eliminate the tumor. The therapeutic candidate is a full-length IgG bi-specific antibody that acts by targeting HER2 and HER3. It is an antibody-dependent cellular cytotoxicity (ADCC)-enhanced Biclonic, which is developed based on Biclonics ENGAGE platform. Currently the drug is in the Phase II stage of clinical trial evaluation for the treatment of Breast Cancer. DX126 262: Hangzhou DAC Biotech DX-126262 is under development for the treatment of HER2-positive or HER2-mutated unresectable locally advanced or metastatic non-squamous NSCLC, Breast Cancer, breast cancer. The drug candidate is an antibody drug conjugate comprising recombinant humanized anti-Her2 monoclonal antibody conjugated to Tub-114. It is formulated as lyophilized powder and administered via intravenous route of administration. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of HER2-positive Breast Cancer. Explore groundbreaking therapies and clinical trials in the Breast Cancer Pipeline. Access DelveInsight's detailed report now! @ New Breast Cancer Drugs Breast Cancer Companies Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc., Horizon Therapeutics, and others Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration Oral Intravenous Subcutaneous Parenteral Topical Breast Cancer Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of Breast Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Breast Cancer Market Drivers and Barriers Scope of the Breast Cancer Pipeline Report Coverage- Global Breast Cancer Companies- Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc., Horizon Therapeutics, and others. Breast Cancer Pipeline Therapies- Oraxol, ARV-471, Ribociclib, E7389, Trastuzumab, GM-CSF, GM-CSF, Trastuzumab, Paclitaxel, Gemcitabine/Carboplatin, Iniparib, and others. Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Breast Cancer Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Breast Cancer Companies, Key Products and Unmet Needs Table of Contents Introduction Breast Cancer Executive Summary Breast Cancer: Overview Breast Cancer Pipeline Therapeutics Breast Cancer Therapeutic Assessment Breast Cancer– DelveInsight's Analytical Perspective Late Stage Products (Phase III) SHR-A1811: Jiangsu HengRui Medicine Co., Ltd. Drug profiles in the detailed report….. Mid Stage Products (Phase II) MCLA-128: Merus N.V. Drug profiles in the detailed report….. Early Stage Products (Phase I) DX126 262: Hangzhou DAC Biotech Drug profiles in the detailed report….. Preclinical and Discovery Stage Products ES2B C001: ExpreS2ion Biotechnologies Drug profiles in the detailed report….. Inactive Products Breast Cancer Companies Breast Cancer Products Breast Cancer Unmet Needs Breast Cancer Market Drivers and Barriers Breast Cancer Future Perspectives and Conclusion Breast Cancer Analyst Views Breast Cancer Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:

The Future Of Forecasting: How AI Can Help Industries Predict Demand For Products That Don't Exist Yet
The Future Of Forecasting: How AI Can Help Industries Predict Demand For Products That Don't Exist Yet

Forbes

time16-07-2025

  • Business
  • Forbes

The Future Of Forecasting: How AI Can Help Industries Predict Demand For Products That Don't Exist Yet

Dileep Kumar Rai is a Global Supply Chain Optimization Expert, Oracle Fusion Cloud architect, and demand forecasting leader. Launching a new product in today's market isn't just risky; it's like setting sail into uncharted waters during a storm, with no compass and relying solely on your instincts to guide you. Throughout my years of working alongside leaders in the automotive, tech, fashion, FMCG and pharmaceutical industries, I've uncovered a widespread yet underappreciated challenge: the 'no-data' dilemma. When introducing something genuinely new to the market, the usual tools—such as ERP forecasts, historical sales curves and even seasoned intuition—often fall short. The result? Overproduction, lost revenue or empty shelves. My Industry Finding: The 'No-Data' Dilemma Through extensive research and direct collaboration with industry innovators, I have identified four recurring pain points that keep executives awake at night: This isn't just an abstract problem; it's a daily operational reality that costs companies millions in missed opportunities and excess inventory. The Cross-Industry AI Forecasting Framework To address this, I developed a proprietary and adaptable AI/ML-powered forecasting framework that combines the art of human judgment with the science of machine learning, tailoring it to each industry's unique dynamics. The Secret Sauce: Understanding The Framework Consider launching a new product as similar to crafting a new recipe: • Data Ingestion: My 'pantry' is stocked with both internal ERP staples and the freshest external ingredients: social buzz, competitor actions, and economic factors signals. • Feature Engineering: Here's the spice rack mixing predictors like launch buzz, product attributes and campaign reach to create a distinctive flavor profile for every launch. • Tailored ML Models: These reflect the cooking techniques of XG-Boost for FMCG, LSTM (long short-term memory) for fashion, and Bayesian models for pharma, each adapted to the industry's unique texture and volatility. • Scenario Simulator: This is my test kitchen, where I experiment with different launch 'recipes,' adjusting prices, channels and competitor responses to determine which flavors succeed. • Executive Dashboard: The tasting table provides real-time insights, confidence intervals and scenario comparisons, empowering leaders to select the best options before introducing them to the market. Industry-Specific Flavor Profiles No two industries have the same palate. This framework adapts like a master chef: Key Drivers: Seasonality, social buzz Modeling Approach: LSTM combined with NLP to capture fast-changing trends and consumer sentiment. Key Drivers: Economic cycles, supply chain lag Modeling Approach: DeepAR paired with time series boosting to handle production volatility and macroeconomic shifts. Key Drivers: Retail promotions, regional preferences Modeling Approach: XGBoost with promotion uplift models to track short-term promotional lifts and geographic variability. Key Drivers: Clinical trial data, prescriber behavior Modeling Approach: Bayesian Models combined with ARIMAX to incorporate clinical data uncertainty and prescribing trends. The Unique Ingredient: Comp Chaining For New Product Launches A cornerstone of my framework is a technique I call Comp Chaining. This method enables us to 'borrow' the sales history of analogous products and blend it with new launch scenarios, even when there's no direct precedent. Here's how Comp Chaining works: • Choose A New Product: Select a target new product and a source-comparable (Comp) product. • Align Sales Histories: Shift the company's sales timeline to match the new launch, week by week. • Adjust For Differences: Use ratios and statistical adjustments to account for differences in initial orders, program length or market conditions. • Blend With AI Forecasts: Where the Comp's history runs out, machine learning fills in the gaps, seasoning the forecast with real-time external data. • Simulate And Refine: Run multiple scenarios, adjusting the blend until the forecast matches the unique profile of your new product. This approach doesn't just copy the past; it creates a new recipe, tailored for today's market and tomorrow's challenges. How To Bring This Framework To Your Organization Final Thoughts: Turning Uncertainty Into A Strategic Ingredient Forecasting demand for new products was once a tedious and uncertain game of guesswork. This framework demonstrates that it doesn't have to be that way. By blending real-world data, AI and Comp Chaining, you can turn uncertainty from a risk into your secret ingredient for growth. In a world where innovation cycles are accelerating and consumer attention is fleeting, the question isn't whether you can afford to add this flavor to your forecasting. The real question is: Can you afford not to? Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store